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Objective: Mutations in the genes encoding the extracellular matrix protein collagen VI (ColVI) cause a spectrum of
disorders with variable inheritance including Ullrich congenital muscular dystrophy, Bethlem myopathy, and
intermediate phenotypes. We extensively characterized, at the clinical, cellular, and molecular levels, 49 patients with
onset in the first 2 years of life to investigate genotype-phenotype correlations.
Methods: Patients were classified into 3 groups: early-severe (18%), moderate-progressive (53%), and mild (29%). ColVI
secretion was analyzed in patient-derived skin fibroblasts. Chain-specific transcript levels were quantified by
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), and mutation identification was performed by
sequencing of complementary DNA.
Results: ColVI secretion was altered in all fibroblast cultures studied. We identified 56 mutations, mostly novel and
private. Dominant de novo mutations were detected in 61% of the cases. Importantly, mutations causing premature
termination codons (PTCs) or in-frame insertions strikingly destabilized the corresponding transcripts. Homozygous
PTC-causing mutations in the triple helix domains led to the most severe phenotypes (ambulation never achieved),
whereas dominant de novo in-frame exon skipping and glycine missense mutations were identified in patients of the
moderate-progressive group (loss of ambulation).
Interpretation: This work emphasizes that the diagnosis of early onset ColVI myopathies is arduous and time-
consuming, and demonstrates that quantitative RT-PCR is a helpful tool for the identification of some mutation-
bearing genes. Moreover, the clinical classification proposed allowed genotype-phenotype relationships to be
explored, and may be useful in the design of future clinical trials.
ANN NEUROL 2010;68:511–520
The ubiquitous extracellular matrix protein collagenVI (ColVI) is composed of 3 chains, a1(VI), a2(VI),
and a3(VI), which display a similar structure with a tri-
ple helical (TH) domain, characterized by the repetition
of the Gly-X-Y amino acid sequence, and flanked by
globular domains homologous to von Willebrand factor
A domains.1,2 These chains assemble in tetramers before
secretion into the extracellular matrix to form micro-
fibrils of ColVI.3
Mutations in the COL6A1, COL6A2, and COL6A3
genes cause ColVI myopathies such as Ullrich congenital
muscular dystrophy (UCMD, Mendelian Inheritance in
Man [MIM]# 254090) and Bethlem myopathy (BM,
MIM# 158810), 2 entities that constitute the extremities
of a continuous clinical spectrum,4,5 with intermediate
phenotypes also observed. Classical UCMD, the severe
and progressive form, presents with hypotonia, muscle
weakness, and motor delay in the first months of life and
is characteristically associated with proximal joint con-
tractures and a striking distal hyperlaxity, as well as severe
respiratory insufficiency.6,7 Classical BM is usually of
later onset and corresponds to a milder phenotype with
slow or static course, characterized by elbow and long
finger flexor contractures.8,9 In addition, mutations in
the ColVI-encoding genes have been associated with 2
other neuromuscular disorders: autosomal dominant
limb-girdle muscular dystrophy in 3 families and, more
recently, autosomal recessive myosclerosis myopathy
(MIM# 255600) in 1 family.10,11 Moreover, although
UCMD was initially described as an autosomal recessive
disorder, autosomal dominant mutations have been
increasingly reported.12–22 On the other hand, although
BM is mostly inherited as an autosomal dominant dis-
ease, rare de novo mutations have been published,23 and
2 recent studies report autosomal recessive muta-
tions.24,25 As a consequence of this great heterogeneity at
the clinical and molecular levels, achieving a definite di-
agnosis is arduous and cumbersome, and establishing ge-
notype-phenotype correlations has proven a difficult task.
Here we present a large cohort of 49 patients with
early onset ColVI myopathy with a variable severity of
presentation and progression, and harboring mutations
in 1 of the ColVI-encoding genes. The vast majority of
the mutations were novel, and more than half of them
were dominant de novo. Quantitative reverse transcrip-
tase polymerase chain reaction (qRT-PCR) proved useful
to identify the mutation-bearing gene in the case of in-
frame insertions and mutations leading to premature ter-
mination codons (PTCs), which greatly reduce the stabil-
ity of the corresponding transcripts. Overall, this study
revealed several genotype-phenotype correlations, provid-
ing new insights into the natural history and course of
ColVI myopathies.
Subjects and Methods
Patients
We studied 49 unrelated index patients (24 males; 25 females)
from different origins (Algeria, Argentina, Belgium, France,
Italy, Madagascar, Portugal, Spain, Switzerland, the Netherlands,
and Turkey). All of them presented with weakness, serum crea-
tine kinase levels no more than 4 normal values, contractures,
and/or distal hyperlaxity. All cases had onset of symptoms in
infancy, and their parents showed no clinical involvement.
Their ages at last examination ranged from 4 to 32 years (mean
age, 16 years). Three patients from consanguineous parents had
affected siblings, whereas the others were sporadic cases. Signed
informed consents were obtained for genetic analysis according
to the French legislation on ethical rules.
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Collagen VI Immunolabeling
Muscle cryosections were available for 33 patients and were
colabeled using monoclonal antibodies against human ColVI
(MAB1944 or MAB3303, Chemicon International, Temecula,
CA) diluted 1:200, and against human perlecan (Chemicon
International) diluted 1:100. Sections were observed with a
Nikon (Melville, NY) E 600 fluorescence microscope.
ColVI immunolabeling in skin fibroblasts from 4 con-
trols and 47 patients was carried out as previously reported.26
Fibroblast cultures from the remaining 2 patients were not
available or did not grow properly and could not be analyzed.
Briefly, confluent cells were cultured in the presence of
0.25mM ascorbic acid for 5 days and stained with the
MAB1944 antibody (Chemicon International), diluted 1:100.
Slides were observed with an Axioplan 2 microscope (Zeiss,
Munich, Germany) equipped with a HBO 100 mercury lamp
(Zeiss), and representative images were obtained using the
Metaview software (Roper Scientific, Trenton, NJ).
RNA Extraction and Reverse Transcription
Total RNA was extracted from confluent fibroblast cultures
using Trizol (Invitrogen, Carlsbad, CA) following the manufac-
turer’s instructions. cDNA was prepared from 1lg of total
RNA using oligo(dT)18 and Superscript II Reverse Transcriptase
as recommended by the manufacturer (Invitrogen).
Quantitative RT-PCR
Chain specific transcripts were quantified from fibroblast-
derived cDNA using quantitative RT-PCR on a LightCycler
480 apparatus (Roche Diagnostics, Mannheim, Germany),
using primers hybridizing to the last C-terminal domain of
each chain, and b-actin as a reference (Supporting Information
Table S1). The 2DDCT method was used to determine the rela-
tive concentrations.27 Quantitative RT-PCR results are
expressed as the mean value of the different experiments per-
formed on at least 2 different cDNA samples for each individ-
ual. Significant differences were determined performing Student
t test (p < 0.05).
Genetic Analysis
Genomic DNA from patients and their relatives was obtained
from blood leucocytes by standard methods. Genetic results of
7 patients were previously reported.26,28 Additional consanguin-
eous and informative nonconsanguineous families were geno-
typed with flanking and intragenic microsatellite markers corre-
sponding to the COL6A1/COL6A2 (D21S156, D21S171,
HCOLINT1, HCOLINT2, D21S2058) and COL6A3
(D2S338, D2S345, D2S2968, HCOLINT, D2S2253) loci to
study the transmission of the parental haplotypes.28
The coding regions of the genes were amplified from
fibroblast-derived cDNA in several overlapping fragments (pri-
mers available on request), and sequenced on the ABI3730 cap-
illary electrophoresis system (Applied Biosystems, Foster City,
CA). Sequences were compared to reference sequences
NM_001848.2 (COL6A1), NM_001849.3 (COL6A2), and
NM_004369.3 (COL6A3) of the National Center for Biotech-
nology Information database. Each potentially pathogenic
change was confirmed on genomic DNA from patients and
their relatives. Nonsynonymous amino acid substitutions were
considered as possibly pathogenic mutations when they affected
a highly conserved residue suspected to play an important role
in the function of the protein and/or when they were not
detected in 100 unrelated control individuals. Alamut (Interac-
tive Biosoftware, North Seattle, WA) and Polyphen (http://coo-
t.embl.de/PolyPhen) softwares were also used to determine the
pathogenicity of the variants.
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TABLE: Summary of the Clinical, Genetic, and Immunolabeling Data in Each Group of Patients
Clinical
Group
Number of
Patients
(male/
female)
Range of Age
(mean) at Last
Examination,
yr
Walked
before
24 Months, %
Mean Age
at Loss of
Ambulation,
yr
Congenital
Contractures, %
Hip
Dislocation, %
Early
severed
9 (7/2) 4–15 (10) Never walked — 89 56
Moderate
progressivee
26 (12/14) 5–37 (16.4) 61.5 10 54 58
Mild 14 (5/9) 5–32 (20) 93 Still
ambulant
57 >64
aFVC ¼ forced vital capacity at last examination. Mean values were calculated from available data (8 early-severe, 20
moderate-progressive, and 8 mild patients).
bPTC ¼ premature termination codon; Ex skip ¼ exon skipping (in frame); IF del/ins ¼ in-frame deletion or insertion.
cH ¼ homozygote; hn ¼ heterozygote de novo; ch ¼ compound heterozygote; uk ¼ unknown.
dTwo patients deceased.
eOne patient deceased.
ColVI ¼ collagen VI.
Results
Patient Phenotypes and Clinical Classification
A great heterogeneity in the severity and course of the
disease was observed among the 49 patients, although all
of them had initial symptoms in the first 2 years of life.
Because of this heterogeneity, and because most of the
patients had long-term follow-up, they were divided into
3 groups according to their maximal motor capacity and
their progression, as proposed by Quijano Roy et al4,29:
the most severe group (early-severe) included 9 patients
(18%) who never achieved ambulation. The moderate-
progressive group was composed of 26 patients (53%)
who were initially able to walk but showed a very pro-
gressive course during childhood or early adulthood.
Indeed, loss of ambulation occurred at a mean age of 10
years (age range, 4–25 years), and only 3 patients above
that age were still able to walk indoors at their last exam-
ination (mean age, 19 years). The less affected group
(mild) included 14 patients (29%) who remained ambu-
latory (mean age of 20 years at last examination). Clini-
cal data are summarized in the Table and detailed in
Supporting Information Table S2.
All patients in the early-severe group presented with
axial or proximal deformities at birth such as torticollis,
kyphoscoliosis, or shoulder, elbow, hip, or knee joint
contractures. These findings were also observed in 9
patients from the moderate-progressive group (35%) and
3 from the mild group (21%). Two ambulatory children
classified at 5 and 9 years in the mild group had antece-
dents of torticollis or proximal joint contractures, but
due to their young ages it is difficult to exclude that they
will not progress to the moderate group. Restrictive respi-
ratory progressive insufficiency was very frequent, and 25
patients (including all those from the early-severe group)
had forced vital capacity <50% of theoretical values.
Thirty-four percent of the patients in the early-severe
and moderate-progressive groups were mechanically ven-
tilated (16% by nasal nocturnal ventilation and 18% via
tracheotomy), and 3 patients died in their teens possibly
due to respiratory complications (see Supporting Infor-
mation Table S2). Spinal involvement (stiffness, with or
without deformity) was observed at birth (4 cases) or in
the course of the disease (43 patients), consisting usually
in scoliosis (31 patients), associated with kyphosis in 16
of them. The remaining patients showed isolated dorsal
kyphosis, lumbar lordosis, or only spinal stiffness without
significant deformity. Cutaneous abnormalities such as
granular rough skin or hypertrophic scars were noted in
22 patients (45%) from the 3 groups, but this may be
underestimated.
ColVI Expression and Secretion Pattern in
Cultured Skin Fibroblasts and Muscle Biopsies
Control fibroblasts abundantly expressed and secreted
ColVI, which formed a dense network (Fig 1). In con-
trast, an abnormal secretion was detected in all the
patient fibroblast cultures (see Table and Supporting In-
formation Table S2). ColVI secretion was either com-
pletely absent (23 samples, 52%), strongly reduced (10
patients, 23%), or slightly reduced (11 cases, 25%). In
these 3 groups, an intracellular retention was frequently
observed (83%). In some cases with reduced (n ¼ 5) or
Mean
FVC, %
(range)a
Spinal
deformities,
%
ColVI Secretion Mutated Gene, %
Predicted
Consequence
%b
Inheritance
%c
Muscle
%
Fibroblast
% COL6A1 COL6A2 COL6A3
30 (15–46) 100 Abnormal
(100)
Abnormal
(100)
44.5 11 44.5 PTC (67),
Missense (11),
Ex skip (22)
H (67),
hn (33)
39.6 (15–70) 100 Abnormal
(76.5)
Abnormal
(100)
28 55 17 PTC (14),
Missense (45),
Ex skip (38),
IF del/ins (3)
H (4),
hn (85),
ch (11)
63 (35–82) 86 Abnormal
(50)
Abnormal
(100)
28 50 22 PTC (33),
Missense (44),
Ex skip (6),
IF del/ins (17)
H (28.5),
hn (36),
ch (28.5),
uk (7)
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strongly reduced (n ¼ 3) secretion, a dotted pattern was
observed. In the 3 remaining patients, the results were
not interpretable.
In contrast, ColVI immunolabeling on muscle sec-
tions was identical to controls in 27% of the patients
(see Supporting Information Table S2). An intracellular
staining was observed in muscle fibers of 18% of the
patients, a peculiar finding that remains to be investi-
gated further.
Mutation Identification in the COL6A Genes
Sequencing of fibroblast-derived cDNA enabled the iden-
tification of 56 different mutations (on 67 alleles), of
which 73% had not been previously reported (Fig 2 and
see Supporting Information Table S2). These mutations
were quite evenly distributed in the 3 genes: 17 in
COL6A1 (30%), 26 in COL6A2 (46%), and 13 in
COL6A3 (23%) (see Fig 2). In 7 consanguineous fami-
lies, homozygosity mapping was useful to direct the
sequencing effort.26,28
A total of 30 patients (61%) harbored dominant de
novo mutations (Supporting Information Tables S2 and
S3). In 1 patient, a single heterozygous mutation was
identified, but no conclusion on its inheritance could be
established for lack of the parents’ DNA. The 18 remain-
ing patients carried recessive mutations, 11 in a homozy-
gous state (22%) and 7 as compound heterozygotes
(14%). It is worth mentioning that only 2 unrelated
patients share the same genomic mutation (see Support-
ing Information Table S2).
All the mutations in COL6A1, as well as all the de
novo mutations in COL6A2 and COL6A3, were located
within the TH domains of the chains. In addition, exon
10 of COL6A1, exon 26 of COL6A2, and intron 16 of
COL6A3 were preferentially mutated (38%, 10%, and
18% of the mutated alleles in each gene, respectively).
PTC-causing mutations were identified in 14
patients (28.5%), including 9 homozygotes and 5 com-
pound heterozygotes, and represented 37% of the
mutated alleles. In 8 of the homozygous patients, the
changes were located upstream or within the TH do-
main, whereas the remaining 1 harbored a large homozy-
gous deletion corresponding to 8 kb of genomic DNA
downstream of exon 26 of COL6A2, leading to the loss
of the C2 domain. Two of the 5 compound heterozygous
patients carried 2 PTC-causing mutations located in the
C1 domain of the a2(VI) chain, and the other 3 patients
combined a PTC-causing mutation, upstream or down-
stream of the TH domain of a2(VI), with a missense
mutation or with an in-frame insertion (see Supporting
Information Table S2).
Missense mutations were identified in 20 patients
(41%) and represented 33% of the mutated alleles. In 75%
of these patients, the mutations involved a glycine residue
of the repeated Gly-X-Y motif of the TH domains, and
were dominant de novo. The remaining 25% were either
homozygote (1 patient), missense compound heterozygote
(1 patient), or combined a missense mutation with a PTC-
causing mutation (2 patients) or an in-frame deletion (1
patient; see Supporting Information Table S2).
Several exon skipping events due to dominant de
novo splice-site mutations were detected in 14 patients
(28.5%), representing 21% of the mutated alleles. Nota-
bly, several patients harbored different genomic muta-
tions leading to identical consequences both at the
mRNA and protein levels. For example, the skipping of
exon 5 in COL6A2 was due to either donor (c.801 G>A
and c.801þ2 T>C) or acceptor (c.736-3 C>G) splice-
site mutations. Similarly, skipping of exon 16 of
COL6A3 was caused by 3 different changes affecting the
same donor site (c.6210þ1 G>A, c.6210þ1 G>T, and
c.6210þ5 G>A), and skipping of exon 18 of COL6A3
was due to either c.6309þ1 G>A or c.6309þ3 A>G
mutations (see Supporting Information Table S2).
Finally, 4 patients harbored small in-frame dele-
tions, affecting 1 or 3 amino acids (1 patient in
COL6A1, another in COL6A3), or an insertion of 3
amino acids in COL6A2 (2 patients).
Additionally, a large number of potentially nonpa-
thogenic variants were also identified, emphasizing the
highly polymorphic nature of these genes (Supporting In-
formation Table S4).
Quantification of Chain-Specific Transcripts
We developed a chain-specific quantitative RT-PCR assay
and determined the transcript levels of each chain for 48
patients. Results were normalized to a control used as
calibrator. Transcripts extracted from fibroblasts from 5
additional control individuals were analyzed and showed
some variability, with levels ranging from 0.58 to 2.21
for COL6A1 (mean value, 1.49 6 0.59), 0.59 to 1.14
for COL6A2 (mean value, 0.95 6 0.13), and 0.64 to
1.13 for COL6A3 (mean value, 0.77 6 0.24). Patients
transcripts levels ranged from 0.03 to 2.43 for COL6A1
(mean value, 0.53 6 0.44), 0.06 to 1.07 for COL6A2
(mean value, 0.35 6 0.23), and 0.03 to 1.3 for COL6A3
(mean value, 0.45 6 0.29). Notably, in 13 of the
patients (26.5%) the levels of only 1 transcript were
0.10 and corresponded to the mutated chain. In 85%
of these cases, the mutation induced either PTCs or in-
frame insertions. In contrast, in the other 35 patients, all
3 chain transcripts showed levels >0.10 and corre-
sponded to patients bearing in-frame deletions or
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missense mutations, combined in 2 cases with PTC-caus-
ing mutations. Mean values of the mRNA levels of the
mutated chains according to the type of mutation are
presented in Figure 3 (individual values are presented in
Supplementary Fig S1). The levels of transcripts harbor-
ing heteroallelic PTC-causing mutations as well as in-
frame insertions were consistently strikingly diminished,
ranging from 0.03 to 0.10, except for 1 patient (0.19),
whereas those with missense mutations and in-frame
deletions were less reduced or close to normal (0.11-
0.99), except for 3 patients (0.10, 0.06, and 2.43).
To rule out transcriptional inhibition, the levels of
pre-mRNA harboring PTC-causing mutations and in-
frame insertions were quantified and were not found dif-
ferent from a control sample, suggesting that the degra-
dation of transcripts harboring these mutations occurred
at the post-transcriptional level (data not shown).
Correlations with the Clinical Phenotype
Taking together all the results presented above, we set
out to establish correlations between the clinical severity
and (1) ColVI secretion in cultured fibroblasts and mus-
cle sections and (2) genotype.
With respect to the degree of abnormality in the
secretion of ColVI in cultured fibroblasts, all patients
from the early-severe group and 83% of the patients clas-
sified as moderate-progressive displayed a complete ab-
sence or a strongly reduced secretion, as opposed to 52%
of the mildly affected patients. In addition, abnormal
ColVI secretion was observed in the muscle section from
all the patients of the early-severe group (see Table and
Supporting Information Table S2).
Genotype-phenotype correlations could be estab-
lished from this study; homozygous PTC-causing muta-
tions (before or within the TH domains) were associated
with the most severe clinical phenotypes (6 patients of 9
in the early-severe group). In contrast, 2 patients carrying
homozygous PTC-causing mutations in the N-terminal
domains displayed a mild clinical phenotype. Addition-
ally, 77% of the patients bearing de novo mutations that
lead to the skipping of exons encoding part of the TH
domains, as well as 66% patients with de novo missense
mutations affecting a glycine residue of the TH Gly-X-Y
motif, were identified in the moderate-progressive group.
Finally, although de novo dominant mutations were
most common overall, recessive inheritance was found in
all 3 clinical categories.
Discussion
Numerous reports have shown the important clinical vari-
ability of UCMD and the complexity of the molecular di-
agnosis, with either recessive or dominant de novo muta-
tions,5,14–16,18,21,30 and possible incomplete penetrance.21
Here, we report a cohort of 49 unrelated patients with
early onset ColVI myopathy, which we characterized at
the clinical, cellular, and molecular levels to establish ge-
notype-phenotype correlations. Although most of the
patients in this series may be included in the UCMD
FIGURE 1: Collagen VI (ColVI) immunolabeling of control-
and patient-derived fibroblasts in culture. (A) Control fibro-
blasts forming a dense ColVI network; (C, E, G, I) ColVI
immunolabeling in fibroblasts from patients as examples of
complete secretion deficiency, strongly reduced secretion,
reduced secretion, and dotted pattern, respectively. Intra-
cellular retention of ColVI can be observed in all these
cases. (B, D, F, H, J) Nuclei were labeled with 4,6-diamidino-
2-phenylindole to control cell density of the cultures. Bar
corresponds to 100lm.
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category, we prefer to use the term ‘‘early onset’’ ColVI
myopathy because of the existence of patients with an
early onset (before 24 months) but a slowly progressive
course (mild patients) who do not present typical charac-
teristics either of UCMD or of BM, and who could
belong to an intermediate group. This overlap has been
also previously stressed by others in patients with later
onset (more similar to typical BM) and a more progres-
sive course than expected (severe or progressive BM).4,31
Clinically, patients showed a large spectrum of se-
verity, with variable impairment of motor and respiratory
function. We chose to classify them according to their
maximal motor capacity rather than respiratory function
due to the variability in respiratory management between
centers, and the close association between mobility loss
and need for respiratory support.32 Therefore, 3 motor
severity groups were established, and distinguished
patients who never achieved ambulation, walked but lost
this ability (or were about to lose it), or were still fully
ambulatory. This classification was useful to infer geno-
type-phenotype correlations in nonambulatory patients,
and in those ambulatory with a long follow-up. However,
molecular data regarding young ambulatory children
should be considered carefully, because they may or may
not follow a progressive and severe course later on. We
tried to investigate early signs of severity or predictors of
progression suggested in a previous study,29 and found
that all nonambulatory patients and 1=3 of moderate-pro-
gressive patients had shown proximal and/or axial ortho-
pedic deformities at birth. However, this sign was also
found in 3 patients still ambulatory in the second or third
decade, meaning that some patients with congenital
FIGURE 3: COL6A transcript levels from control- and
patient-derived fibroblasts. Only patients harboring a single
type of mutation were taken into account. Transcript levels
of the mutated chain were classified according to the type
of mutation identified. Statistical analysis could not be car-
ried out in samples harboring COL6A2 in-frame insertion
because only 1 homozygous patient was identified. Data
are presented as mean values 6 standard deviation (**p <
0.01, *p < 0.02). PTC 5 premature termination codon; del 5
deletion; ins 5 insertion. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
FIGURE 2: Schematic representation of mutations identified in the COL6A1, COL6A2, and COL6A3 genes. Exons are shown as
blue vertical rectangles above the corresponding protein. The signal peptide (SP) and the domains are indicated below the dia-
gram (TH 5 triple helical domain; N10-N1 5 N-terminal domains; C1-C5 5 C-terminal domains). Recessive and dominant
de novo mutations are indicated above or below the genes, respectively. Premature termination codon-causing mutations are
indicated in blue, missense mutations in red, and in-frame deletions and insertions in green and black, respectively. Symbols
refer to the clinical phenotype of the patients: early-severe as squares, moderate-progressive as circles, and mild as triangles.
Letters a through g indicate that patients are compound heterozygotes and refer to the 2 mutations identified in the same
patient. Shaded areas containing several mutations are enlarged.
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contractures or deformities of the proximal joints, neck, or
spine may have a relatively good prognosis. Finally, in our
series, respiratory function was more severely impaired in
the oldest patients of both the early-severe and moderate-
progressive groups, but not in the mild patients.
At the molecular level, mutations were largely pri-
vate (only 1 mutation detected in 2 unrelated patients),
and the vast majority of them are novel. The cDNA-
based strategy, unveiling the consequences of a genomic
mutation, allowed us to identify mutations that would
have been difficult to detect at the genomic level, such as
the intronic mutation c.904-39 A>G affecting a branch
point and leading to COL6A1 exon 11 skipping. We also
identified the largest genomic deletion in the COL6A2
gene so far. Importantly, 61% of the mutations were
dominant de novo, in accordance to previous studies,16
which is a limitation for linkage analysis approaches. We
report 5 dominant mutations already identified as de
novo,15,16,18,21 indicating that some regions of the
COL6A genes could be more susceptible to neomuta-
tions. Most of the mutations affecting the Gly-X-Y repe-
titions were located in the N-terminal part of the TH
domains, emphasizing the importance of this region.
Indeed, it has been demonstrated by in vitro studies that
such mutations are compatible with the integration of
the mutated chain in the tetramer, leading to reduced
microfibril formation efficiency, ultimately exerting a
dominant deleterious effect.33 In contrast with other
reports,14,18 we observed that most of the patients at the
severe end of the clinical spectrum (early-severe and
moderate-progressive phenotypes) display a striking
reduction or complete absence of ColVI secretion, as
opposed to only half of the least affected patients.
According to our results, the association of clinical symp-
toms and a striking anomaly of ColVI secretion could be
predictive of a more severe course.
A cellular mechanism that regulates the expression
of ColVI is the degradation of abnormal transcripts.
Indeed, we showed that all types of mutations can lead
to reduced transcript levels. Moreover, quantitative analysis
of pre-mRNA levels suggested that this regulation does not
occur at the transcriptional level (data not shown), but that
these mutations destabilize the corresponding mRNA mol-
ecules, most strikingly in the case of PTC-causing muta-
tions and in-frame insertions. Reduced transcripts levels
were also reported in 4 patients harboring splicing muta-
tions leading to either exon skipping or PTCs.34 It is
worth noting that, in the case of PTC-causing mutations
as well as in-frame insertions, the quantification of tran-
script levels allowed us to detect the mutated gene prior to
sequencing. In the case of PTCs, this regulatory mecha-
nism is most likely the nonsense mediated decay (NMD),
as previously reported in UCMD and BM patients.17,35
Nevertheless, we previously reported and confirm here that
the homozygous nonsense mutation in 1 patient escaped
the NMD process by skipping the mutation-bearing
exon.26 Moreover, the presence of a heteroallelic missense
mutation masked the impact of the PTC-causing mutation
in 2 compound heterozygous patients.
Genotype-phenotype correlations have started to
emerge recently, on limited groups of patients.16 The
present study on a large cohort of patients also reveals
several striking observations. In agreement with previous
reports,21,30,36,37 all patients harboring recessive PTC-
causing mutations in the TH region exhibit an early-
severe phenotype (ie, never acquired ambulation). How-
ever, 2 milder patients carry homozygous PTC-causing
mutations located in N-terminal domains. As mentioned
before, for 1 of them we demonstrated that skipping of
the mutated exon allowed the production of a shorter
but functional protein.26 We have not been able to im-
plicate the same mechanism in the other patient, who is
still young (9 years old) and already shows scoliosis and
respiratory problems, signs suggestive of a progressive
course. Another mildly affected patient exhibited a PTC-
causing mutation in the signal peptide, combined with a
missense mutation, which likely modulates the deleteri-
ous effect of the PTC.
In addition, dominant splice-site mutations causing
exon skipping as well as Gly-missense mutations were
mostly observed in patients of the moderate-progressive
category. Nevertheless, it is worth noting that skipping of
exon 16 of COL6A3, recently described as the most com-
mon consequence of splice-site mutations, was detected
also in patients with early-severe phenotypes, as observed
by others.16,18 This severity is probably due to the prox-
imity of the unique cysteine residue encoded by exon 17
of COL6A3, which is thought to be implicated in the di-
sulfide bonds that assemble dimers and tetramers prior
to secretion.38
However, it is important to note that similar types of
mutations or mutations in the same domain of the protein
do not necessary lead to comparable phenotype severity,
because they have been identified in patients with variable
clinical severity by us and others.11,15,39 Indeed, one can-
not exclude that the numerous polymorphisms identified
in these genes may contribute to the variability of the clini-
cal phenotype. Further analysis of the segregation of these
variants in affected individuals is necessary.
In conclusion, our data on this large cohort of
patients with early onset ColVI myopathies reinforce previ-
ous reports relating to the variability of the clinical spectrum
and the complexity of the diagnosis for this condition.
Although the final diagnosis of ColVI myopathies may only
ANNALS of Neurology
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be made on mutation identification in 1 of the COL6A
genes, we propose that quantitative RT-PCR is helpful in
accelerating the identification of the mutation-bearing gene.
The frequency of dominant de novo mutations is very im-
portant to consider in the context of genetic counseling.
Moreover, the identification of genotype-phenotype correla-
tions may be useful in the design of future clinical trials.
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